How do you pay?

How to pay the least

Ask for the cash price

Osvyrti

Osvyrti is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Osvyrti’s cash price, and one or two other pharmacies too.
  2. Osvyrti’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameOsvyrti
Authorized genericdenosumab-desu
Regular genericdenosumab-desu
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Osvyrti?
The original
–
–

Brand nameThe maker’s card

AccordCares Co-Pay Program

Savings card from Accord BioPharma

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a treatment

Sign up on osvyrti.com 

Or call 1-866-258-7151.

In the maker’s words

“Eligible patients may pay as little as $0 co-pay per OSVYRTI treatment.”

From the maker’s offer on osvyrti.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Osvyrti itself, from the same company, sold without the brand name, and usually for less. For now Osvyrti is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Osvyrti is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for:

  • of postmenopausal women with osteoporosis at high risk for fracture
  • to increase bone mass in men with osteoporosis at high risk for fracture
  • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
  • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

Source: the FDA label for Osvyrti (Accord BioPharma Inc.), July 7, 2026. Full label on DailyMed 

Good to know